Treatment-Resistant Depression Treatment Market Share 2023 to 2033 | By Sandoz, H. Lundbeck, AbbVie, AstraZeneca

The global Treatment-Resistant Depression Treatment Market size is expected to reach US$ 1.69 billion by 2023, with a projected compound annual growth rate (CAGR) of 9.0% between 2023 and 2033, owing to the rising prevalence of depression and anxiety disorders in adults and an ageing population. By 2033, the market is estimated to be worth approximately US$ 4.0 billion. Because of increased awareness of treatment-resistant depression, many market participants are developing complex medications that can be supplied via intranasal and intravenous routes rather than traditional oral administration.

Get a PDF Sample with Latest Market Insights@ https://www.futuremarketinsights.com/reports/sample/rep-gb-15965

While standard antidepressants can take weeks to operate and deliver only partial or poor outcomes when taken orally, intranasal medication has been found to provide improved advantages within hours of administration. For example, a January 2022 study published in Pharmacopsychiatry discovered that Novartis Pharmaceuticals’ MIJ821, a novel pipeline antidepressant, produced a more significant reduction in depression episodes among patients within 24 hours of monthly infusion.

Furthermore, intranasal esketamine paired with a novel oral antidepressant was found to be more efficacious than placebo plus oral treatment. Esketamine intranasally alleviated depressed symptoms fast and delayed relapse time. Furthermore, increased R&D of sophisticated pharmaceuticals using different means of administration is likely to promote drug demand and market growth.

The World Health Organisation (WHO) reports that the prevalence of mental health concerns has increased by 13% in the last decade. According to the US Department of Health and Human Services (HHS), about 4.1 million adolescents aged 12 to 17 had a major depressive episode (MDE) in 2020, with 2.9 million having a severe MDE.

Get a Discount@ https://www.futuremarketinsights.com/request-discount/rep-gb-15965

Key Takeaways from the Market Study

• The global Treatment-Resistant Depression Treatment market was worth $1.55 billion USD by the end of 2022.
• Market demand expanded at a 3.3% CAGR from 2018 to 2022.
• With a 49% market share, the NMDA sector accounts for the majority of the market.
• The Hospital Pharmacies category dominates the market by Distribution Channel, accounting for 47% of the market.
• Revenues for Treatment-Resistant Depression Treatment are expected to grow at a 9.0% CAGR from 2023 to 2033.
• By 2033, the market for Treatment-Resistant Depression Treatment is expected to reach US$ 4.0 billion.

“The rising geriatric population is one of the factors that is anticipated to boost the growth of treatment-resistance depression treatment market, as the treatment-resistance depression treatment is high in this age group population,” remarks an FMI analyst.

Competitive Landscape

Prominent players in the Treatment-Resistant Depression Treatment market are Janssen Global Services, LLC, AbbVie Inc., Sandoz International GmbH (Novartis AG), H. Lundbeck A/S, Par Pharmaceutical (Endo International plc), Otsuka Pharmaceutical Co., Ltd., and AstraZeneca, among others.

Customization Available Upon Request@ https://www.futuremarketinsights.com/customization-available/rep-gb-15965

Recent Developments:

• Merck Sharp & Dohme LLC launched a Phase II a research trial in August 2022 to assess the safety and efficacy of MK-1942 in treatment-resistant depressive patients.
• Novartis Pharmaceuticals stated in July 2022 that a Phase 2 clinical trial of MIJ821 (ketamine) for treatment-resistant depressive disorders would begin in September 2022.
• At the American Psychiatric Association annual meeting in New Orleans in May 2022, COMPASS Pathways presented positive data for the Phase IIb study of COMP360 psilocybin therapy for Treatment-Resistant Depression Treatment.
• Denova Biopharma received FDA approval in February 2022 to begin a Phase 2b clinical research to evaluate the efficacy and safety of DB104 (liafensine) in individuals with treatment-resistant mood disorder.

Key Segments Covered in the Treatment-Resistant Depression Treatment Industry Analysis

Treatment-Resistant Depression Treatment Market by Drug Type:

• NMDA
• Antidepressants
• Antipsychotics
• Others

Treatment-Resistant Depression Treatment Market by Distribution Channel:

• Hospital Pharmacies
• Drug Stores & Retail Pharmacies
• Online Pharmacies

Treatment-Resistant Depression Treatment Market by Region:

• North America
• Latin America
• Europe
• South Asia & Pacific
• East Asia
• Middle East & Africa

About Future Market Insights, Inc.

Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn | Twitter | Blogs